Skip to main content
. 2017 Feb 14;7:42260. doi: 10.1038/srep42260

Figure 1. BMSCs pre-treated with different concentrations of IL-1β alleviated neuropathic pain in a concentration dependent manner.

Figure 1

(A) Flow cytometry analysis of isolated BMSCs. More than 90% of BMSCs were CD29 (+) and CD90 (+), and less than 2% of BMSCs were CD45 (+) or CD31 (+). (B) BMSCs were positive for vimentin (V9) and had osteogenesis and adipogenesis potential. (C) Inhibition of mechanical allodynia and thermal hyperalgesia by i.t. injection of BMSCs pre-treated with different concentrations of IL-1β. *P < 0.05, compared with PBS group; n = 6 cultures/group for cell experience; 24 rats in total for behavioral test and n = 6 rats/group. Statistical significance was determined using a two-way repeated-measures ANOVA followed by Bonferroni’s post-hoc test. All data are expressed as the mean ± SEM.